The molecular determinants and signaling pathways responsible for hematogenous leukocyte trafficking during peripheral neuroinflammation are incompletely elucidated. Chemokine ligand/receptor pair CCL2/CCR2 has been pathogenically implicated in the acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barré syndrome (GBS). We evaluated the role of CCR2 in peripheral neuroinflammation utilizing a severe murine experimental autoimmune neuritis (sm-EAN) model. Sm-EAN was induced in 8–12 week old female SJL CCR2 knockout (CCR2KO), heterozygote (CCR2HT) and wild type (CCR2WT) mice, and daily neuromuscular severity scores and weights recorded. In vitro and in vivo splenocyte proliferation and cytokine expression assays, and sciatic nerve Toll-like receptor (TLR) 2, TLR4 and CCL2 expression assays were performed to evaluate systemic and local innate immune activation at disease onset. Motor nerve electrophysiology and sciatic nerve histology were also performed to characterize the inflammatory neuropathy at expected peak severity. To further determine the functional relevance of CCR2 in sm-EAN, 20 mg/kg CCR2 antagonist, RS 102895 was administered daily for 5 days to a cohort of CCR2WT mice following sm-EAN disease onset, with efficacy compared to 400 mg/kg human intravenous immunoglobulin (IVIg). CCR2KO mice were relatively resistant to sm-EAN compared to CCR2WT and CCR2HT mice, associated with attenuated peripheral nerve demyelinating neuritis. Partial CCR2 gene deletion did not confer any protection against sm-EAN. CCR2KO mice demonstrated similar splenocyte activation or proliferation profiles, as well as TLR2, TLR4 and CCL2 expression to CCR2WT or CCR2HT mice, implying a direct role for CCR2 in sm-EAN pathogenesis. CCR2 signaling blockade resulted in rapid, near complete recovery from sm-EAN following disease onset. RS 102895 was significantly more efficacious than IVIg. CCR2 mediates pathogenic hematogenous monocyte trafficking into peripheral nerves, with consequential demyelination in sm-EAN. CCR2 is amenable to pharmacologic blockade, making it a plausible drug target for GBS.
Chiang S, Ubogu EE (2013) The role of chemokines in Guillain-Barre syndrome. Muscle Nerve 48: 320–330. doi: 10.1002/mus.23829
[4]
Lu MO, Zhu J (2011) The role of cytokines in Guillain-Barre syndrome. J Neurol 258: 533–548. doi: 10.1007/s00415-010-5836-5
[5]
Orlikowski D, Chazaud B, Plonquet A, Poron F, Sharshar T, et al. (2003) Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis. J Neuroimmunol 134: 118–127. doi: 10.1016/s0165-5728(02)00393-4
[6]
Press R, Pashenkov M, Jin J, Link H (2003) Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Immunol 23: 259–267.
[7]
Meyer zu H？rste G, Hartung H, Kieseier B (2007) From bench to bedside—experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 3: 198–211. doi: 10.1038/ncpneuro0452
[8]
Calida D, Kremlev S, Fujioka T, Hilliard B, Ventura E, et al. (2000) Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12. J Neuroimmunol 107: 1–7. doi: 10.1016/s0165-5728(00)00249-6
[9]
Xia R, Yosef N, Ubogu E (2010) Clinical, electrophysiological and pathologic correlations in a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. J Neuroimmunol 219: 54–63. doi: 10.1016/j.jneuroim.2009.11.019
[10]
Ubogu EE (2013) Chemokine-dependent signaling pathways in the peripheral nervous system. Methods Mol Biol 1013: 17–30. doi: 10.1007/978-1-62703-426-5_2
[11]
Mahad D, Callahan M, Williams K, Ubogu E, Kivis？kk P, et al. (2006) Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129: 212–223. doi: 10.1093/brain/awh655
[12]
Kiefer R, Kieseier BC, Stoll G, Hartung HP (2001) The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 64: 109–127. doi: 10.1016/s0301-0082(00)00060-5
[13]
Xia RH, Yosef N, Ubogu EE (2010) Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome. Neuropathol Appl Neurobiol 36: 388–398. doi: 10.1111/j.1365-2990.2010.01092.x
[14]
Bennett JL, Elhofy A, Charo I, Miller SD, Dal Canto MC, et al. (2007) CCR2 regulates development of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Viral Immunol 20: 19–33. doi: 10.1089/vim.2006.0068
[15]
Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, et al. (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552–2561. doi: 10.1172/jci119798
[16]
Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW (2013) Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol 15: 357–363. doi: 10.1016/j.intimp.2012.11.016
[17]
Xia R, Yosef N, Ubogu E (2010) Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: technical aspects and normative data. Muscle Nerve 41: 850–856. doi: 10.1002/mus.21588
[18]
Ubogu EE, Yosef N, Xia RH, Sheikh KA (2012) Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model. J Peripher Nerv Syst 17: 53–61. doi: 10.1111/j.1529-8027.2012.00375.x
[19]
Jessen KR, Mirsky R, Morgan L (1987) Axonal signals regulate the differentiation of non-myelin-forming Schwann cells: an immunohistochemical study of galactocerebroside in transected and regenerating nerves. J Neurosci 7: 3362–3369.
[20]
Kruisbeek AM (2001) Isolation of mouse mononuclear cells. Curr Protoc Immunol Chapter 3: Unit 3 1.
[21]
Yosef N, Xia R, Ubogu E (2010) Development and characterization of a novel human in vitro blood-nerve barrier model using primary endoneurial endothelial cells. J Neuropathol Exp Neurol 69: 82–97. doi: 10.1097/nen.0b013e3181c84a9a
[22]
Reddy CL, Yosef N, Ubogu EE (2013) VEGF-A165 potently induces human blood-nerve barrier endothelial cell proliferation, angiogenesis, and wound healing in vitro. Cell Mol Neurobiol 33: 789–801. doi: 10.1007/s10571-013-9946-3
[23]
Yosef N, Ubogu EE (2012) GDNF restores human blood-nerve barrier function via RET tyrosine kinase-mediated cytoskeletal reorganization. Microvasc Res 83: 298–310. doi: 10.1016/j.mvr.2012.01.005
[24]
Yosef N, Ubogu EE (2012) alpha(M)beta(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barre syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro. J Cell Physiol 227: 3857–3875. doi: 10.1002/jcp.24100
[25]
Yosef N, Ubogu EE (2013) An immortalized human blood-nerve barrier endothelial cell line for in vitro permeability studies. Cell Mol Neurobiol 33: 175–186. doi: 10.1007/s10571-012-9882-7
[26]
Viquez OM, Valentine HL, Friedman DB, Olson SJ, Valentine WM (2007) Peripheral nerve protein expression and carbonyl content in N,N-diethlydithiocarbamate myelinopathy. Chem Res Toxicol 20: 370–379. doi: 10.1021/tx6003453
[27]
Goethals S, Ydens E, Timmerman V, Janssens S (2010) Toll-like receptor expression in the peripheral nerve. Glia 58: 1701–1709. doi: 10.1002/glia.21041
[28]
Deshmane S, Kremlev S, Amini S, Sawaya B (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29: 313–326. doi: 10.1089/jir.2008.0027
[29]
Berchiche YA, Gravel S, Pelletier ME, St-Onge G, Heveker N (2011) Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, Galphai signaling, and receptor internalization. Mol Pharmacol 79: 488–498. doi: 10.1124/mol.110.068486
[30]
Volpe S, Cameroni E, Moepps B, Thelen S, Apuzzo T, et al. (2012) CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. PLoS One 7: e37208. doi: 10.1371/journal.pone.0037208
[31]
Yao Y, Tsirka SE (2010) The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem 285: 31509–31516. doi: 10.1074/jbc.m110.124891
[32]
Siebert H, Sachse A, Kuziel WA, Maeda N, Bruck W (2000) The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol 110: 177–185. doi: 10.1016/s0165-5728(00)00343-x
[33]
Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 14: 1142–1149. doi: 10.1038/nn.2887
[34]
Ydens E, Lornet G, Smits V, Goethals S, Timmerman V, et al. (2013) The neuroinflammatory role of Schwann cells in disease. Neurobiol Dis 55: 95–103. doi: 10.1016/j.nbd.2013.03.005
[35]
Meyer zu H？rste G, Hu W, Hartung H, Lehmann H, Kieseier B (2008) The immunocompetence of Schwann cells. Muscle Nerve 37: 3–13. doi: 10.1002/mus.20893
[36]
Duan R, Chen Z, Bao L, Quezada H, Nennesmo I, et al. (2004) CCR5 deficiency does not prevent P0 peptide 180-199 immunized mice from experimental autoimmune neuritis. Neurobiol Dis 16: 630–637. doi: 10.1016/j.nbd.2004.04.007
[37]
Ubogu EE (2011) Chemokine receptors as specific anti-inflammatory targets in peripheral nerves. Endocr Metab Immune Disord Drug Targets 11: 141–153. doi: 10.2174/187153011795564124
[38]
Kieseier B, Tani M, Mahad D, Oka N, Ho T, et al. (2002) Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 125: 823–834. doi: 10.1093/brain/awf070
[39]
Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173: 310–317. doi: 10.1111/j.1749-6632.2009.04813.x
[40]
Charo I, Ransohoff R (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610–621. doi: 10.1056/nejmra052723
[41]
Zlotnik A, Yoshie O (2012) The chemokine superfamily revisited. Immunity 36: 705–716. doi: 10.1016/j.immuni.2012.05.008
